Document 0597
 DOCN  M9590597
 TI    New drug for CMV in trials. Clearinghouse, P.O. Box 6003, Rockville, MD
       20849-6003. 800-458-5231 ext. 5023.
 DT    9509
 SO    Treat Review. 1995 Jan;(no 16):3. Unique Identifier : AIDSLINE
       AIDS/95700311
 AB    Two new trials are studying treatment of CMV retinitis with an antisense
       drug called ISIS 2922. This drug affects the way the CMV works, i.e., it
       may be able to destroy the virus without harming the patient. One study
       uses ISIS 2922 alone and the other combines it with ganciclovir.
       Participants must have CMV retinitis in one or both eyes and the
       condition must have progressed at least once while being treated with
       ganciclovir or foscarnet. ISIS 2922 will be injected directly into the
       eye globe; ganciclovir will be given intravenously. Participants must
       not be intolerant to ganciclovir, the infection must be peripheral, and
       there must be no opportunistic infection outside of the eye. More
       information can be obtained by calling The Network at (800) 734-7104.
 DE    Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       Cytomegalovirus Retinitis/*DRUG THERAPY  Drug Administration Routes
       Drug Therapy, Combination  Eye  Ganciclovir/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  Human  Infusions, Intravenous  NEWSLETTER
       ARTICLE  RANDOMIZED CONTROLLED TRIAL  CLINICAL TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).